A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
ConclusionsTrabectedin, in combination with PLD, may have clinical benefits in Japanese patients with relapsed advanced ovarian cancer. The recommended dosage of trabectedin for further study in this population is 1.1 mg/m2 once every 21 days.Clinical trial registration number: JapicCTI-163164
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Fallopian Tube Cancer | Gastroenterology | Japan Health | Ovarian Cancer | Ovaries | Peritoneal Cancer | Pharmaceuticals | Study | Toxicology